Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial

• Published in: Scientific reports Vol. 6; no. 1; p. 31838
• Main Authors: Li, Pan, Gu, Ying, Yang, Yawei, Chen, Lizhi, Liu, Junmei, Gao, Lihong, Qin, Yongwen, Cai, Quancai, Zhao, Xianxian, Wang, Zhuo, Ma, Liping
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.08.2016; Nature Publishing Group
• Subjects: 631/154/109/1940; 631/154/436/108; 631/154/436/1729; 631/154/436/2388; Adenosine - administration & dosage; Adenosine - analogs & derivatives; Adenosine - pharmacokinetics; Adult; Anticoagulants; Bleeding; Blood platelets; Cardiovascular disease; China; Clinical trials; Clopidogrel; Dose-Response Relationship, Drug; Drug dosages; Drug therapy; Electron tubes; Female; Healthy Volunteers; Hospitals; Humanities and Social Sciences; Humans; Male; multidisciplinary; Pharmacokinetics; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - pharmacokinetics; Receptors, Purinergic P2Y12 - metabolism; Science; Ticagrelor; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Young Adult

Ticagrelor has a greater antiplatelet efficacy than clopidogrel but may be accompanied by an increased risk of bleeding. This study evaluated the antiplatelet effect and pharmacokinetic profile of low-dose ticagrelor in healthy Chinese volunteers. Thirty healthy subjects were randomized to receive s...